| Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells MD Hoban, GJ Cost, MC Mendel, Z Romero, ML Kaufman, AV Joglekar, ... Blood 125 (17), 2597-2604, 2015 | 369 | 2015 |
| Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease MD Hoban, SH Orkin, DE Bauer Blood 127 (7), 839-848, 2016 | 201 | 2016 |
| Wild-type adenoviruses from groups A–F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent DM Appledorn, A Kiang, A McBride, H Jiang, S Seregin, JM Scott, ... Gene therapy 15 (12), 885-901, 2008 | 58 | 2008 |
| A genome editing primer for the hematologist MD Hoban, DE Bauer Blood 127 (21), 2525-2535, 2016 | 39 | 2016 |
| Dissecting the Mechanism of Histone Deacetylase Inhibitors to Enhance the Activity of Zinc Finger Nucleases Delivered by Integrase-Defective Lentiviral Vectors AV Joglekar, L Stein, M Ho, MD Hoban, RP Hollis, DB Kohn Human gene therapy 25 (7), 599-608, 2014 | 22 | 2014 |
| The human ankyrin 1 promoter insulator sustains gene expression in a β-globin lentiviral vector in hematopoietic stem cells Z Romero, B Campo-Fernandez, J Wherley, ML Kaufman, F Urbinati, ... Molecular Therapy-Methods & Clinical Development 2, 15012, 2015 | 20 | 2015 |
| CRISPResso: sequencing analysis toolbox for CRISPR genome editing L Pinello, MC Canver, MD Hoban, SH Orkin, DB Kohn, DE Bauer, ... bioRxiv, 031203, 2016 | 18 | 2016 |
| Delivery of genome editing reagents to hematopoietic stem/progenitor cells MD Hoban, Z Romero, GJ Cost, M Mendel, M Holmes, DB Kohn Current protocols in stem cell biology, 5B. 4.1-5B. 4.10, 2016 | 11 | 2016 |
